急性缺血性卒中患者，推荐不用链激酶(1a级)。
For patients with acute ischemic stroke, we recommend against streptokinase (Grade 1a).
肌球蛋白，轻链激酶，克隆号：K36，单克隆抗体。
临床试验证明重组链激酶为一安全、有效的新型溶栓药。
The clinical studies demonstrated that r-SK is a safe and effective new type thrombolytic agent.
胸膜腔内滴注链激酶治疗胸膜腔感染这是胸膜腔积液治疗的进步吗？
Intrapleural streptokinase for pleural infection a step forward in managing pleural effusions?
链激酶和尿激酶溶栓是重要的，是天冬酰胺酶在治疗白血病细胞生长剂。
Streptokinase and urokinase are important in thrombolytics, and asparaginase is used as a cytostatic agent in the treatment of leukemia.
重组链激酶的血管开通率高，不良反应主要为轻度过敏反应，低血压及轻度出血。
The patency of infarct-related coronary artery was high. The side effects of r -SK were allergic reaction , hypotension and mild bleeding.
首要效力观察终点为基于“通用链激酶与t-PA针对冠脉闭塞（GUSTO）”定义的中度或重度的出血；
The key safety end point was severe or moderate bleeding according to the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) definition.
首要效力观察终点为基于“通用链激酶与t-PA针对冠脉闭塞（GUSTO）”定义的中度或重度的出血；
The key safety end point was severe or moderate bleeding according to the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) definition.
应用推荐